当前位置: 首页 >> 检索结果
181. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.
作者: Zev A Wainberg.;Davide Melisi.;Teresa Macarulla.;Roberto Pazo Cid.;Sreenivasa R Chandana.;Christelle De La Fouchardière.;Andrew Dean.;Igor Kiss.;Woo Jin Lee.;Thorsten O Goetze.;Eric Van Cutsem.;A Scott Paulson.;Tanios Bekaii-Saab.;Shubham Pant.;Richard A Hubner.;Zhimin Xiao.;Huanyu Chen.;Fawzi Benzaghou.;Eileen M O'Reilly.
来源: Lancet. 2023年402卷10409期1272-1281页
Pancreatic ductal adenocarcinoma remains one of the most lethal malignancies, with few treatment options. NAPOLI 3 aimed to compare the efficacy and safety of NALIRIFOX versus nab-paclitaxel and gemcitabine as first-line therapy for metastatic pancreatic ductal adenocarcinoma (mPDAC).
182. Expedited transfer to a cardiac arrest centre for non-ST-elevation out-of-hospital cardiac arrest (ARREST): a UK prospective, multicentre, parallel, randomised clinical trial.
作者: Tiffany Patterson.;Gavin D Perkins.;Alexander Perkins.;Tim Clayton.;Richard Evans.;Matthew Dodd.;Steven Robertson.;Karen Wilson.;Adam Mellett-Smith.;Rachael T Fothergill.;Paul McCrone.;Miles Dalby.;Philip MacCarthy.;Sam Firoozi.;Iqbal Malik.;Roby Rakhit.;Ajay Jain.;Jerry P Nolan.;Simon R Redwood.; .
来源: Lancet. 2023年402卷10410期1329-1337页
The International Liaison Committee on Resuscitation has called for a randomised trial of delivery to a cardiac arrest centre. We aimed to assess whether expedited delivery to a cardiac arrest centre compared with current standard of care following resuscitated cardiac arrest reduces deaths.
185. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
作者: Hope S Rugo.;Aditya Bardia.;Frederik Marmé.;Javier Cortés.;Peter Schmid.;Delphine Loirat.;Olivier Trédan.;Eva Ciruelos.;Florence Dalenc.;Patricia Gómez Pardo.;Komal L Jhaveri.;Rosemary Delaney.;Theresa Valdez.;Hao Wang.;Monica Motwani.;Oh Kyu Yoon.;Wendy Verret.;Sara M Tolaney.
来源: Lancet. 2023年402卷10411期1423-1433页
Sacituzumab govitecan demonstrated significant progression-free survival benefit over chemotherapy in the phase 3 TROPiCS-02 trial in patients with pretreated, endocrine-resistant hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+ and HER2-) metastatic breast cancer with limited treatment options. Here, we report the protocol-specified final analysis of overall survival and endpoints by trophoblast cell-surface antigen 2 (Trop-2) expression and other variables.
187. Clinical and cost-effectiveness of nurse-delivered sleep restriction therapy for insomnia in primary care (HABIT): a pragmatic, superiority, open-label, randomised controlled trial.
作者: Simon D Kyle.;A Niroshan Siriwardena.;Colin A Espie.;Yaling Yang.;Stavros Petrou.;Emma Ogburn.;Nargis Begum.;Leonie F Maurer.;Barbara Robinson.;Caroline Gardner.;Victoria Lee.;Stephanie Armstrong.;Julie Pattinson.;Sam Mort.;Eleanor Temple.;Victoria Harris.;Ly-Mee Yu.;Peter Bower.;Paul Aveyard.
来源: Lancet. 2023年402卷10406期975-987页
Insomnia is prevalent and distressing but access to the first-line treatment, cognitive behavioural therapy (CBT), is extremely limited. We aimed to assess the clinical and cost-effectiveness of sleep restriction therapy, a key component of CBT, which has the potential to be widely implemented.
189. Cause-specific mortality by county, race, and ethnicity in the USA, 2000-19: a systematic analysis of health disparities.
Large disparities in mortality exist across racial-ethnic groups and by location in the USA, but the extent to which racial-ethnic disparities vary by location, or how these patterns vary by cause of death, is not well understood. We aimed to estimate age-standardised mortality by racial-ethnic group, county, and cause of death and describe the intersection between racial-ethnic and place-based disparities in mortality in the USA, comparing patterns across health conditions.
191. Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial.
作者: Christopher W Ryan.;Catherine M Tangen.;Elisabeth I Heath.;Mark N Stein.;Maxwell V Meng.;Ajjai S Alva.;Sumanta K Pal.;Igor Puzanov.;Joseph I Clark.;Toni K Choueiri.;Neeraj Agarwal.;Robert G Uzzo.;Naomi B Haas.;Timothy W Synold.;Melissa Plets.;Ulka N Vaishampayan.;Brian M Shuch.;Ian M Thompson.;Primo N Lara.
来源: Lancet. 2023年402卷10407期1043-1051页
Patients undergoing resection of renal cell carcinoma are at risk of disease relapse. We evaluated the effectiveness of the mammalian target of rapamycin inhibitor everolimus administered after surgery.
192. The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review.
The risk of sexual transmission of HIV from individuals with low-level HIV viraemia receiving antiretroviral therapy (ART) has important public health implications, especially in resource-limited settings that use alternatives to plasma-based viral load testing. This Article summarises the evidence related to sexual transmission of HIV at varying HIV viral load levels to inform messaging for people living with HIV, their partners, their health-care providers, and the wider public.
194. Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial.
作者: Frank R Lin.;James R Pike.;Marilyn S Albert.;Michelle Arnold.;Sheila Burgard.;Theresa Chisolm.;David Couper.;Jennifer A Deal.;Adele M Goman.;Nancy W Glynn.;Theresa Gmelin.;Lisa Gravens-Mueller.;Kathleen M Hayden.;Alison R Huang.;David Knopman.;Christine M Mitchell.;Thomas Mosley.;James S Pankow.;Nicholas S Reed.;Victoria Sanchez.;Jennifer A Schrack.;B Gwen Windham.;Josef Coresh.; .
来源: Lancet. 2023年402卷10404期786-797页
Hearing loss is associated with increased cognitive decline and incident dementia in older adults. We aimed to investigate whether a hearing intervention could reduce cognitive decline in cognitively healthy older adults with hearing loss.
195. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.
作者: Joe Y Chang.;Steven H Lin.;Wenli Dong.;Zhongxing Liao.;Saumil J Gandhi.;Carl M Gay.;Jianjun Zhang.;Stephen G Chun.;Yasir Y Elamin.;Frank V Fossella.;George Blumenschein.;Tina Cascone.;Xiuning Le.;Jenny V Pozadzides.;Anne Tsao.;Vivek Verma.;James W Welsh.;Aileen B Chen.;Mehmet Altan.;Reza J Mehran.;Ara A Vaporciyan.;Stephen G Swisher.;Peter A Balter.;Junya Fujimoto.;Ignacio I Wistuba.;Lei Feng.;J Jack Lee.;John V Heymach.
来源: Lancet. 2023年402卷10405期871-881页
Stereotactic ablative radiotherapy (SABR) is the standard treatment for medically inoperable early-stage non-small-cell lung cancer (NSCLC), but regional or distant relapses, or both, are common. Immunotherapy reduces recurrence and improves survival in people with stage III NSCLC after chemoradiotherapy, but its utility in stage I and II cases is unclear. We therefore conducted a randomised phase 2 trial of SABR alone compared with SABR with immunotherapy (I-SABR) for people with early-stage NSCLC.
197. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
作者: Athimalaipet V Ramanan.;Pierre Quartier.;Nami Okamoto.;Ivan Foeldvari.;Alberto Spindler.;Šárka Fingerhutová.;Jordi Antón.;Zhongkai Wang.;Gabriella Meszaros.;Joana Araújo.;Ran Liao.;Stuart Keller.;Hermine I Brunner.;Nicolino Ruperto.; .; .
来源: Lancet. 2023年402卷10401期555-570页
Juvenile idiopathic arthritis can be refractory to some or all treatment regimens, therefore new medications are needed to treat this population. This trial assessed the efficacy and safety of baricitinib, an oral Janus kinase 1/2-selective inhibitor, versus placebo in patients with juvenile idiopathic arthritis.
198. The unfinished agenda of communicable diseases among children and adolescents before the COVID-19 pandemic, 1990-2019: a systematic analysis of the Global Burden of Disease Study 2019.
Communicable disease control has long been a focus of global health policy. There have been substantial reductions in the burden and mortality of communicable diseases among children younger than 5 years, but we know less about this burden in older children and adolescents, and it is unclear whether current programmes and policies remain aligned with targets for intervention. This knowledge is especially important for policy and programmes in the context of the COVID-19 pandemic. We aimed to use the Global Burden of Disease (GBD) Study 2019 to systematically characterise the burden of communicable diseases across childhood and adolescence.
199. Predicting COVID-19 infection risk in people who are immunocompromised by antibody testing.
作者: Ratna Wijaya.;Marina Johnson.;Nicola Campbell.;Beth Stuart.;Adam Kelly.;Nicole Tipler.;Tobias Menne.;Matthew J Ahearne.;Victoria Willimott.;Anna Bowzyk Al-Naeeb.;Christopher P Fox.;Graham P Collins.;Ann O'Callaghan.;Andrew J Davies.;David Goldblatt.;Sean H Lim.; .
来源: Lancet. 2023年402卷10396期99-102页 200. Graft dysfunction in compassionate use of genetically engineered pig-to-human cardiac xenotransplantation: a case report.
作者: Muhammad M Mohiuddin.;Avneesh K Singh.;Linda Scobie.;Corbin E Goerlich.;Alison Grazioli.;Kapil Saharia.;Claire Crossan.;Allen Burke.;Cinthia Drachenberg.;Cihan Oguz.;Tianshu Zhang.;Billeta Lewis.;Alena Hershfeld.;Faith Sentz.;Ivan Tatarov.;Sarah Mudd.;Gheorghe Braileanu.;Kathryn Rice.;John F Paolini.;Kent Bondensgaard.;Todd Vaught.;Kasinath Kuravi.;Lori Sorrells.;Amy Dandro.;David Ayares.;Christine Lau.;Bartley P Griffith.
来源: Lancet. 2023年402卷10399期397-410页
A genetically engineered pig cardiac xenotransplantation was done on Jan 7, 2022, in a non-ambulatory male patient, aged 57 years, with end-stage heart failure, and on veno-arterial extracorporeal membrane oxygenation support, who was ineligible for an allograft. This report details our current understanding of factors important to the xenotransplantation outcome.
|